Overview

A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Single-Arm, Open-Label, Multicenter Clinical Trial. To observe the efficacy and safety of TQB2450 in patients of non-hodgkin lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.